Literature DB >> 31650954

Predictors of SIV recrudescence following antiretroviral treatment interruption.

Mykola Pinkevych1, Christine M Fennessey2, Deborah Cromer1, Carolyn Reid2, Charles M Trubey2, Jeffrey D Lifson2, Brandon F Keele2, Miles P Davenport1.   

Abstract

There is currently a need for proxy measures of the HIV rebound competent reservoir (RCR) that can predict viral rebound after combined antiretroviral treatment (cART) interruption. In this study, macaques infected with a barcoded SIVmac239 virus received cART beginning between 4- and 27 days post-infection, leading to the establishment of different levels of viral dissemination and persistence. Later treatment initiation led to higher SIV DNA levels maintained during treatment, which was significantly associated with an increased frequency of SIV reactivation and production of progeny capable of causing rebound viremia following treatment interruption. However, a 100-fold increase in SIV DNA in PBMCs was associated with only a 2-fold increase in the frequency of reactivation. These data suggest that the RCR can be established soon after infection, and that a large fraction of persistent viral DNA that accumulates after this time makes relatively little contribution to viral rebound.

Entities:  

Keywords:  HIV; immunity; infectious disease; latency; microbiology; virus

Mesh:

Substances:

Year:  2019        PMID: 31650954      PMCID: PMC6917497          DOI: 10.7554/eLife.49022

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  52 in total

Review 1.  The Alphabet Soup of HIV Reservoir Markers.

Authors:  Radwa R Sharaf; Jonathan Z Li
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

2.  How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?

Authors:  David M Margolis; Steven G Deeks
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

3.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

4.  Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants.

Authors:  Bonnie Hiener; Bethany A Horsburgh; John-Sebastian Eden; Kirston Barton; Timothy E Schlub; Eunok Lee; Susanne von Stockenstrom; Lina Odevall; Jeffrey M Milush; Teri Liegler; Elizabeth Sinclair; Rebecca Hoh; Eli A Boritz; Daniel Douek; Rémi Fromentin; Nicolas Chomont; Steven G Deeks; Frederick M Hecht; Sarah Palmer
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

5.  Viremic relapse after HIV-1 remission in a perinatally infected child.

Authors:  Katherine Luzuriaga; Hannah Gay; Carrie Ziemniak; Keri B Sanborn; Mohan Somasundaran; Kaitlin Rainwater-Lovett; John W Mellors; Daniel Rosenbloom; Deborah Persaud
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

6.  Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.

Authors:  Scott G Hansen; Julia C Ford; Matthew S Lewis; Abigail B Ventura; Colette M Hughes; Lia Coyne-Johnson; Nathan Whizin; Kelli Oswald; Rebecca Shoemaker; Tonya Swanson; Alfred W Legasse; Maria J Chiuchiolo; Christopher L Parks; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Michael Piatak; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2011-05-11       Impact factor: 49.962

7.  The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

Authors:  Alexandra M Bender; Francesco R Simonetti; Mithra R Kumar; Emily J Fray; Katherine M Bruner; Andrew E Timmons; Katherine Y Tai; Katharine M Jenike; Annukka A R Antar; Po-Ting Liu; Ya-Chi Ho; Dana N Raugi; Moussa Seydi; Geoffrey S Gottlieb; Afam A Okoye; Gregory Q Del Prete; Louis J Picker; Joseph L Mankowski; Jeffrey D Lifson; Janet D Siliciano; Greg M Laird; Dan H Barouch; Janice E Clements; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2019-07-10       Impact factor: 31.316

8.  Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.

Authors:  Christine M Fennessey; Mykola Pinkevych; Taina T Immonen; Arnold Reynaldi; Vanessa Venturi; Priyanka Nadella; Carolyn Reid; Laura Newman; Leslie Lipkey; Kelli Oswald; William J Bosche; Matthew T Trivett; Claes Ohlen; David E Ott; Jacob D Estes; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2017-05-04       Impact factor: 6.823

9.  New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Authors:  C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

10.  Defective proviruses rapidly accumulate during acute HIV-1 infection.

Authors:  Katherine M Bruner; Alexandra J Murray; Ross A Pollack; Mary G Soliman; Sarah B Laskey; Adam A Capoferri; Jun Lai; Matthew C Strain; Steven M Lada; Rebecca Hoh; Ya-Chi Ho; Douglas D Richman; Steven G Deeks; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2016-08-08       Impact factor: 53.440

View more
  8 in total

1.  CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

Authors:  Afam A Okoye; Derick D Duell; Yoshinori Fukazawa; Benjamin Varco-Merth; Alejandra Marenco; Hannah Behrens; Morgan Chaunzwa; Andrea N Selseth; Roxanne M Gilbride; Jason Shao; Paul T Edlefsen; Romas Geleziunas; Mykola Pinkevych; Miles P Davenport; Kathleen Busman-Sahay; Michael Nekorchuk; Haesun Park; Jeremy Smedley; Michael K Axthelm; Jacob D Estes; Scott G Hansen; Brandon F Keele; Jeffery D Lifson; Louis J Picker
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

2.  Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

Authors:  Adrienne E Swanstrom; Taina T Immonen; Kelli Oswald; Cathi Pyle; James A Thomas; William J Bosche; Lorna Silipino; Michael Hull; Laura Newman; Vicky Coalter; Adam Wiles; Rodney Wiles; Jacob Kiser; David R Morcock; Rebecca Shoemaker; Randy Fast; Matthew W Breed; Joshua Kramer; Duncan Donohue; Tyler Malys; Christine M Fennessey; Charles M Trubey; Claire Deleage; Jacob D Estes; Jeffrey D Lifson; Brandon F Keele; Gregory Q Del Prete
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

3.  The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth.

Authors:  Ryan V Moriarty; Athena E Golfinos; Dane D Gellerup; Hannah Schweigert; Jaffna Mathiaparanam; Alexis J Balgeman; Andrea M Weiler; Thomas C Friedrich; Brandon F Keele; Miles P Davenport; Vanessa Venturi; Shelby L O'Connor
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.752

4.  Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.

Authors:  Widade Ziani; Anya Bauer; Hong Lu; Xiaolei Wang; Xueling Wu; Katharine J Bar; Hui Li; Dongfang Liu; George M Shaw; Ronald S Veazey; Huanbin Xu
Journal:  J Virol       Date:  2021-04-12       Impact factor: 6.549

5.  Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.

Authors:  Taina T Immonen; Christine M Fennessey; Leslie Lipkey; Abigail Thorpe; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele
Journal:  PLoS Pathog       Date:  2021-06-18       Impact factor: 6.823

6.  Down but not out.

Authors:  Erin T Larragoite; Adam M Spivak
Journal:  Elife       Date:  2019-12-23       Impact factor: 8.140

7.  Models of SIV rebound after treatment interruption that involve multiple reactivation events.

Authors:  Christiaan H van Dorp; Jessica M Conway; Dan H Barouch; James B Whitney; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2020-10-01       Impact factor: 4.475

Review 8.  Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.

Authors:  Xiaolei Wang; Huanbin Xu
Journal:  Viruses       Date:  2021-02-21       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.